Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in St Germain En Laye – page 38

3 345 clinical trials in St Germain En Laye, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
St Germain En Laye at a glance
3 345
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 345 trials in St Germain En Laye

Open in trial search

A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Testing the Safety and Effects of TUB-030 in Patients with Advanced Head and Neck Cancer or Non-Small-Cell Lung Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:TUB-030
  • Sponsor:Gilead Sciences Inc.

A study comparing trifluridine, tipiracil, and fruquintinib versus trifluridine and tipiracil alone for patients with metastatic stomach or esophageal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fruquintinib
  • Sponsor:Fondation Franc.Cancerologie Digestive

Breast cancer+2

Recruiting

A Study of Datopotamab Deruxtecan for Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer That Did Not Respond to Hormone Therapy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Datopotamab Deruxtecan
  • Sponsor:AstraZeneca AB

A Study of ACP-204 Tartrate for Adults With Lewy Body Dementia Psychosis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Acadia Pharmaceuticals Inc.

A Follow-up Study of Mezagitamab in Adults with Chronic Primary Immune Thrombocytopenia to Evaluate Long-term Safety and Effectiveness

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mezagitamab
  • Sponsor:Takeda Development Center Americas Inc.

Study of ipilimumab and nivolumab injected into tumors before surgery in patients with stage III melanoma that can be removed by surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Unicancer

Testing sacituzumab govitecan and trastuzumab deruxtecan in alternating pattern for patients with HER2-low triple-negative breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sacituzumab Govitecan
  • Sponsor:Unicancer

A Study Testing ACP-204 Tartrate Compared to Placebo for Adults with Lewy Body Dementia Psychosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Acadia Pharmaceuticals Inc.

A Study of ADX-324 to Prevent Attacks in Patients With Hereditary Angioedema

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ADX-324
  • Sponsor:Adarx Pharmaceuticals Inc.
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Centre Hospitalier Universitaire De Montpellier

Study of Lisocabtagene Maraleucel as First Treatment for Adults with Primary Central Nervous System Lymphoma Who Cannot Have a Stem Cell Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in St Germain En Laye

What the registry says about research in the country

01 Hematologic Oncology

Investigating innovative combination therapies for follicular lymphoma, comparing mosunetuzumab plus lenalidomide against standard treatments to improve progression-free survival in previously untreated patients.

  • Advanced lymphoma treatments
  • Targeted therapy combinations
  • Novel therapeutic approaches

Research focuses on enhancing treatment outcomes for high-risk lymphoma patients.

02 Breast Cancer Research

Evaluating treatment strategies for elderly women with HER2-negative breast cancer, examining the effectiveness of combined chemotherapy and hormone therapy based on genomic profiling.

  • Age-specific treatment protocols
  • Personalized therapy approaches
  • Genomic-guided interventions

Studies aim to optimize treatment outcomes for senior patients while considering their specific needs.

03 Neurological Disorders

Investigating treatment optimization for Secondary Progressive Multiple Sclerosis patients, focusing on the safety and efficacy of disease-modifying therapy withdrawal in stable patients over 50.

  • Treatment discontinuation studies
  • Age-specific MS management
  • Long-term disease monitoring

Research aims to enhance quality of life while maintaining disease stability.

04 Maternal Health

Examining preventive strategies for pregnancy-associated hypertension and pre-eclampsia through controlled trials of acetylsalicylic acid treatment in pregnant women with chronic hypertension.

  • Maternal-fetal outcomes
  • Preventive interventions
  • Pregnancy complications

Focus on reducing maternal and fetal morbidity through preventive care.

05 Endocrine Surgery

Investigating the effects of preoperative cholecalciferol supplementation on post-thyroidectomy outcomes, specifically focusing on preventing hypocalcemia complications.

  • Surgical outcome optimization
  • Preventive supplementation
  • Post-operative care

Research aims to improve patient recovery and reduce hospital stays after thyroid surgery.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.